Latest news with #Form10-Q
Business Insider
a day ago
- Business
- Business Insider
Wetouch receives Nasdaq non-compliance notification
Wetouch (WETH) Technology announced that it has received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC, dated May 27, 2025, indicating that the company is not in compliance with Nasdaq Listing Rule 5250(c)(1). This rule requires timely filing of periodic reports with the U.S. Securities and Exchange Commission. The notification was issued because the company has not yet filed its Quarterly Report on Form 10-Q for the period ended March 31, 2025 and the company remains delinquent in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. This delay triggered the non-compliance notice under the continued listing requirements. In accordance with Nasdaq's procedures, the company has until June 20, 2025, to submit to Nasdaq a plan to regain compliance. If Nasdaq accepts the plan, Wetouch may be granted up to 180 calendar days from the original due date of the Form 10-K, or until October 13, 2025, to file the Form 10-K and Form 10-Q and thereby regain compliance. The company intends to file the Form 10-K and Form 10-Q as soon as practicable thereafter, and expects to regain compliance within the allowed timeframe. Confident Investing Starts Here:
Business Insider
a day ago
- Business
- Business Insider
TechTarget receives non-compliance notification from Nasdaq
TechTarget (TTGT) announced that the company received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC on May 27, 2025 notifying the company that it is not in compliance with Nasdaq Listing Rule 5250(c)(1), because the company had not yet timely filed its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025 or, at the time of receipt of the Notice, its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The Notice has no immediate effect on the listing or trading of the company's securities on the Nasdaq Global Select Market. The Notice stated that the company has until June 16, 2025 to submit a plan to regain compliance with the Rule with respect to the Form 10-K and the Form 10-Q. If Nasdaq accepts the company's plan to regain compliance, then Nasdaq may grant the company until October 13, 2025 to file the Form 10-K and the Form 10-Q to regain compliance with the Rule. Confident Investing Starts Here:
Business Insider
a day ago
- Business
- Business Insider
VSee Health receives Nasdaq notice on delayed 10-Q filing
VSee Health (VSEE) announced that on May 23, 2025, the company received a notice from The Nasdaq Stock Market LLC stating that because the company had not yet filed its Quarterly Report on Form 10-Q for the period ended March 31, 2025, and its Annual Report on Form 10-K for the period ended December 31, 2024, the company is not in compliance with Nasdaq's listing rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. The Nasdaq notice has no immediate effect on the listing or trading of the company's common stock or its public warrants on The Nasdaq Capital Market. According to the notice, the company has until June 24, 2025 to submit a plan to regain compliance. If Nasdaq accepts the company's plan, then Nasdaq may grant the company up to 180 calendar days from the initial Form 10-K due date, or until October 13, 2025, to regain compliance. The company intends to take the necessary steps to regain compliance with Nasdaq's listing rules and file the Form 10-Q and Form 10-K as soon as practicable. Confident Investing Starts Here:
Business Upturn
a day ago
- Business
- Business Upturn
Oak Woods Acquisition Corporation Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q
New York, May 30, 2025 (GLOBE NEWSWIRE) — Oak Woods Acquisition Corporation. (Nasdaq: OAKU) (the 'Company') today announced it received a delinquency notification letter from Nasdaq on May 27, 2025, which indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the delayed filing of the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2025 (the 'Quarterly Report'). The Nasdaq Listing Rule requires listed companies to timely file all required periodic financial reports with the U.S. Securities and Exchange Commission (the 'SEC'). This notification has no immediate effect on the listing of the Company's securities on Nasdaq. The Notice states that the Company has 60 calendar days to submit a plan to regain compliance and if the Nasdaq accepts such plan, the Nasdaq can grant an exception of up to 180 calendar days from the Quarterly Report's due date, or until November 17, 2025 (the 'Compliance Date'), to regain compliance. The Notification Letter does not impact the Company's listing on The Nasdaq Capital Market at this time. The Company is currently in the final stages of completing work on its 10-Q for the quarter ended March 31, 2025. While the Company has not yet filed its Quarterly Report on Form 10-Q, it is working diligently with its independent registered public accounting firm to complete the remaining audit procedures. The delay in filing is not due to any disagreement with the Company's auditors and the Company expects to file the Form 10-Q promptly upon completion of the audit review process. About Oak Woods Acquisition Oak Woods Acquisition Corporation is a blank check company organized for the purpose of effecting a merger, capital stock exchange, asset acquisition, or other similar business combination with one or more businesses or entities. On August 11, 2023, Oak Woods Acquisition Corporation, a Cayman Islands corporation (' Oak Woods '), entered into a Merger Agreement and Plan of Reorganization (the ' Merger Agreement ') with Oak Woods Merger Sub, Inc., a Cayman Islands corporation and a wholly owned subsidiary of Oak Woods (' Merger Sub '), Huajin (China) Holdings Limited, a Cayman Islands corporation (' Huajin ') and Xuehong Li, in his capacity as the representative of the Huajin shareholde (' Shareholders' Representative '), as amended by its agreement to extend the date by which a Business Combination is required to be completed to June 28, 2024, dated March 23, 2024, and subsequently by the First Amendment to the Merger Agreement entered into by Oak Woods, Huajin, Merger Sub, and the Shareholders' Representative on June 26, 2024 extending the time to complete its business combination to September 28, 2024. On October 1, 2024 the Company announced that, as approved by the shareholders of the Company at the Extraordinary General Meeting adjourned from September 25, 2024 and held on September 26, 2024 (the 'September EGM'), the following proposals were approved thereby amending the Amended and Restated Articles and Memorandum of Association of the Company to give the Company the right to extend the date by which the Company has to complete a business combination from September 28, 2024 to March 28, 2025, by depositing into the Trust Account $172,500 per for each one-month extension, on or prior to the date of the applicable deadline, for up to six (6) times. On March 26, 2025 the Company announced that, as approved by the shareholders of the Company at the Extraordinary General Meeting held on March 20, 2025 (the 'March EGM'), the following proposals were approved thereby amending the Amended and Restated Articles and memorandum of Association to give the Company the right to extend the date by which the Company has to complete a business combination from March 28, 2025 to September 28, 2025, by depositing into the Trust Account $172,500 per for each one-month extension, on or prior to the date of the applicable deadline, for up to six (6) times. As of May 30, 2025, our Sponsor has timely deposited all prior monthly extension deposits and again deposited $172,500 into our Trust Account, thereby extending the time available to the Company to complete our initial business combination until June 28, 2025. Forward Looking Statements This press release includes forward-looking statements that involve risks and uncertainties. Forward looking statements are statements that are not historical facts. Such forward- looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Contact: Lixin ZhengChief Executive OfficerOak Woods Acquisition Corporation (+1) 403-561-7750
Yahoo
a day ago
- Business
- Yahoo
Celularity Receives Nasdaq Notice Regarding Form 10-Q
FLORHAM PARK, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ('Celularity' or the 'Company'), a cellular and regenerative medicine company, today announced that on May 28, 2025, Nasdaq notified the Company that it did not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2025. Based on this latest notice, the Company is not in compliance with Listing Rule 5250 (c)(1), which requires the Company to timely file all required periodic financial reports with the Securities and Exchange Commission. The Notice received from Nasdaq has no immediate effect on the listing or trading of the Company's shares. Nasdaq has provided the Company 60 calendar days to submit a plan to regain compliance. If Nasdaq accepts the Company's plan, then Nasdaq may grant the Company an exception until November 17, 2025, to regain compliance with the Nasdaq Listing Rules. The Company continues to work diligently to complete its Form 10-Q for the period ended March 31, 2025, after which the Company anticipates maintaining compliance with its SEC reporting obligations. About Celularity Celularity Inc. (Nasdaq: CELU) is a regenerative and cellular medicine company developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Celularity believes that by harnessing the placenta's unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies. For more information, visit Forward-Looking Statements This press release includes 'forward-looking statements' (as defined under Federal securities laws). These forward-looking statements include, without limitation, statements regarding: (i) our future sales or sales growth; (ii) our expectations for future financial results, including levels of net sales; (iii) our expectations regarding new products including our 510K products; and (iv) future demand for our products. All statements other than statements of historical facts are 'forward-looking statements,' including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as 'anticipate,' 'believe,' 'can,' 'could,' 'continue,' 'expect,' 'improving,' 'may,' 'observed,' 'potential,' 'promise,' 'should,' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Celularity's current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks,' and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including those risk factors set forth under the caption 'Risk Factors' in Celularity's annual report on Form 10-K and Form 10-K/A for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) on May 8, 2025 and May 21, 2025, respectively, and other filings with the SEC. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Celularity does not presently know, or that Celularity currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect Celularity's current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing Celularity's views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. Carlos RamirezSenior Vice President, Celularity in to access your portfolio
